137 related articles for article (PubMed ID: 37693608)
1. Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression.
Mondal DK; Xie C; Buraschi S; Iozzo RV
bioRxiv; 2023 Aug; ():. PubMed ID: 37693608
[TBL] [Abstract][Full Text] [Related]
2. Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression.
Mondal DK; Xie C; Pascal GJ; Buraschi S; Iozzo RV
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2317760121. PubMed ID: 38652741
[TBL] [Abstract][Full Text] [Related]
3. Decorin evokes reversible mitochondrial depolarization in carcinoma and vascular endothelial cells.
Neill T; Xie C; Iozzo RV
Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1355-C1373. PubMed ID: 36036446
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.
Harris AR; Perez MJ; Munson JM
BMC Cancer; 2018 Jul; 18(1):718. PubMed ID: 29976154
[TBL] [Abstract][Full Text] [Related]
5. Decorin deficiency promotes hepatic carcinogenesis.
Horváth Z; Kovalszky I; Fullár A; Kiss K; Schaff Z; Iozzo RV; Baghy K
Matrix Biol; 2014 Apr; 35():194-205. PubMed ID: 24361483
[TBL] [Abstract][Full Text] [Related]
6. Decorin has an appetite for endothelial cell autophagy.
Neill T; Torres A; Buraschi S; Iozzo RV
Autophagy; 2013 Oct; 9(10):1626-8. PubMed ID: 23989617
[TBL] [Abstract][Full Text] [Related]
7. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
8. Decorin is a devouring proteoglycan: Remodeling of intracellular catabolism via autophagy and mitophagy.
Buraschi S; Neill T; Iozzo RV
Matrix Biol; 2019 Jan; 75-76():260-270. PubMed ID: 29080840
[TBL] [Abstract][Full Text] [Related]
9. Catabolic degradation of endothelial VEGFA via autophagy.
Neill T; Chen CG; Buraschi S; Iozzo RV
J Biol Chem; 2020 May; 295(18):6064-6079. PubMed ID: 32209654
[TBL] [Abstract][Full Text] [Related]
10. The Role of Decorin and Biglycan Signaling in Tumorigenesis.
Diehl V; Huber LS; Trebicka J; Wygrecka M; Iozzo RV; Schaefer L
Front Oncol; 2021; 11():801801. PubMed ID: 34917515
[TBL] [Abstract][Full Text] [Related]
11. Oncosuppressive roles of decorin through regulation of multiple receptors and diverse signaling pathways.
Xie C; Mondal DK; Ulas M; Neill T; Iozzo RV
Am J Physiol Cell Physiol; 2022 Mar; 322(3):C554-C566. PubMed ID: 35171698
[TBL] [Abstract][Full Text] [Related]
12. Decorin is an autophagy-inducible proteoglycan and is required for proper in vivo autophagy.
Gubbiotti MA; Neill T; Frey H; Schaefer L; Iozzo RV
Matrix Biol; 2015 Oct; 48():14-25. PubMed ID: 26344480
[TBL] [Abstract][Full Text] [Related]
13. Decorin causes autophagy in endothelial cells via Peg3.
Buraschi S; Neill T; Goyal A; Poluzzi C; Smythies J; Owens RT; Schaefer L; Torres A; Iozzo RV
Proc Natl Acad Sci U S A; 2013 Jul; 110(28):E2582-91. PubMed ID: 23798385
[TBL] [Abstract][Full Text] [Related]
14. Decorin-evoked paternally expressed gene 3 (PEG3) is an upstream regulator of the transcription factor EB (TFEB) in endothelial cell autophagy.
Neill T; Sharpe C; Owens RT; Iozzo RV
J Biol Chem; 2017 Sep; 292(39):16211-16220. PubMed ID: 28798237
[TBL] [Abstract][Full Text] [Related]
15. Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis.
Mao L; Yang J; Yue J; Chen Y; Zhou H; Fan D; Zhang Q; Buraschi S; Iozzo RV; Bi X
Matrix Biol; 2021 Jan; 95():1-14. PubMed ID: 33065248
[TBL] [Abstract][Full Text] [Related]
16. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor.
Moscatello DK; Santra M; Mann DM; McQuillan DJ; Wong AJ; Iozzo RV
J Clin Invest; 1998 Jan; 101(2):406-12. PubMed ID: 9435313
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs.
Goldoni S; Iozzo RV
Int J Cancer; 2008 Dec; 123(11):2473-9. PubMed ID: 18798267
[TBL] [Abstract][Full Text] [Related]
18. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1α, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3.
Neill T; Painter H; Buraschi S; Owens RT; Lisanti MP; Schaefer L; Iozzo RV
J Biol Chem; 2012 Feb; 287(8):5492-506. PubMed ID: 22194599
[TBL] [Abstract][Full Text] [Related]
19. Decorin as a multivalent therapeutic agent against cancer.
Neill T; Schaefer L; Iozzo RV
Adv Drug Deliv Rev; 2016 Feb; 97():174-85. PubMed ID: 26522384
[TBL] [Abstract][Full Text] [Related]
20. Small Leucine Rich Proteoglycans (decorin, biglycan and lumican) in cancer.
Appunni S; Anand V; Khandelwal M; Gupta N; Rubens M; Sharma A
Clin Chim Acta; 2019 Apr; 491():1-7. PubMed ID: 30629950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
